<DOC>
	<DOCNO>NCT02869295</DOCNO>
	<brief_summary>This first human , open-label , sequential dose escalation expansion Phase 1 study NKTR-214 adult patient locally advance metastatic solid tumor .</brief_summary>
	<brief_title>A Phase 1 Dose Escalation Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Histologically confirm diagnosis locally advance metastatic solid tumor . Received 1 2 prior line therapy . Life expectancy &gt; 12 week . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Measurable disease per RECIST v1.1 . Demonstrated adequate organ function within 14 day treatment initiation . Subjects must recover effect prior chemotherapy , immunotherapy , prior system anticancer therapy , radiotherapy surgery . Women childbearing potential must agree use highly effective method birth control . All participant must agree use double barrier contraception study participation least 2 month last dose study drug . Additional criterion may apply . Use investigational agent investigational device within 28 day administration first dose NKTR214 . Females pregnant breastfeeding . Participants active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease require systemic steroid immunosuppressive agent . Active central nervous system ( CNS ) metastases . Prior surgery radiotherapy within 14 day therapy . Participants &lt; 28 day since last chemotherapy , immunotherapy , biological therapy , &lt; 14 day approve tyrosine kinase inhibitor ( TKI ) therapy ( sunitinib , sorafenib , vemurafenib , dabrafenib , cobretinib ) , systemic inhale steroid therapy dose great 10mg prednisone equivalent administration first dose study medication . Participants ' inability adhere tolerate protocol study procedure . Additional criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metastatic Solid Tumors</keyword>
	<keyword>Locally Advanced Solid Tumors</keyword>
</DOC>